Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Duration in Neoadjuvant Esophageal SCC
NCT06663059Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tangdu Hospital. Started Oct 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06663059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663059.